Migdal Insurance & Financial Holdings Ltd. Has $37,000 Holdings in Boston Scientific Corporation $BSX

Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 72.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 344 shares of the medical equipment provider’s stock after purchasing an additional 145 shares during the quarter. Migdal Insurance & Financial Holdings Ltd.’s holdings in Boston Scientific were worth $37,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Bessemer Group Inc. raised its stake in shares of Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Swedbank AB raised its stake in shares of Boston Scientific by 114.5% in the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, Director Ellen M. Zane sold 2,901 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total transaction of $296,598.24. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,467,460.16. This represents a 10.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 180,204 shares of company stock valued at $18,544,846 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 0.8%

Shares of NYSE:BSX opened at $100.20 on Thursday. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company’s 50-day moving average price is $100.96 and its two-hundred day moving average price is $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $148.47 billion, a P/E ratio of 53.58, a P/E/G ratio of 2.03 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BSX shares. Needham & Company LLC restated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. BTIG Research reaffirmed a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Morgan Stanley upped their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.